Cargando…
Clinical Trials in Oncology and Defining Benefit
In response to the recently published article by Goldberg et al., which discusses changing aspects of clinical trial design in oncology, this letter to the editor elaborates on the definitions of benefits, efficacy, and futility.
Autor principal: | Sorscher, Steven |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AlphaMed Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759827/ https://www.ncbi.nlm.nih.gov/pubmed/29133517 http://dx.doi.org/10.1634/theoncologist.2017-0476 |
Ejemplares similares
-
Circulating cell-free DNA use for diagnosing cholangiocarcinoma
por: Sorscher, Steven
Publicado: (2019) -
CHEK2 Pathogenic Germline Variants in Patients With NSCLC
por: Sorscher, Steven
Publicado: (2022) -
Why the length of recurrence-free survival or ‘lead-times’ can be
misleading. Comment on: Callesen LB, Takacova T, Hamfjord J, et
al. Circulating DNA in patients undergoing loco-regional treatment
of colorectal cancer metastases: a systematic review and
meta-analysis
por: Sorscher, Steven
Publicado: (2023) -
Defining Suicide in Clinical Trials—How Do We Fare?
por: Mitra, Sayantanava, et al.
Publicado: (2021) -
Extrahepatic Bile Duct Resection in Gallbladder Carcinoma: Differentiated Discussion about Risk and Oncological Benefit
por: Fetzner, Ulrich Klaus, et al.
Publicado: (2010)